Endo International to acquire Par Pharmaceutical for $8.05B, PENTAX continues to work with FDA on scope infections & more – 7 GI/endoscopy company key notes

Here are seven recent news updates on gastroenterology and endoscopy companies.

Advertisement

Ernest Mario, director with Boston Scientific, sold 50,000 shares of company stock for a total transaction value of $904,500, according to a Dakota Financial News report.

Biotechnology company ColonaryConcepts enrolled its first patient in a phase 2 clinical trial of colon preparation. 

Commonwealth Laboratories, based in Salem, Mass., launched IBSchek, a blood test designed to detect irritable bowel syndrome.

Endo International will acquire Par Pharmaceutical for $8.05 billion in cash and stock, according to a report by The New York Times. The deal will result in one of the five largest generic drug companies in the country.

Mauna Kea Technologies‘ Cellvizio technology received a CE mark for use in minimally invasive laparoscopic surgical indications.

Mederi Therapeutics announced two milestones for its Stretta Therapy. Stretta has now been used for the treatment of GERD in 18,000 cases. The therapy has also received new regulatory approval in the Australia, Argentina, India, Mexico, South Africa and South Korea markets.

PENTAX Medical reiterated its commitment to working with the FDA to address infection risk associated with duodenoscopes. 

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.

More articles on gastroenterology:
7 statistics on gastroenterologist compensation by practice setting
GI physician leader to know: Dr. James Scolapio of UF Health
GI physician leader to know: Dr. Helen Shields of Harvard Medical School

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.